Literature DB >> 15848679

Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease.

K Inoue1, M Yoshiba.   

Abstract

Hepatitis C virus (HCV) is the most common cause of end-stage liver disease in transplant recipients. Progression of recurrent HCV infection is accelerated. Cyclosporine is not only an immunosuppressive drug, but also an anti-HCV drug. We reported here the beneficial effect of combined interferon and cyclosporine treatment for chronic hepatitis C. We recommend this protocol for established HCV-related graft disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15848679     DOI： 10.1016/j.transproceed.2004.11.041

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


  19 in total

1.  Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells.

Authors:  Li Ye; Jieliang Li; Ting Zhang; Xu Wang; Yizhong Wang; Yu Zhou; Jinping Liu; Hemant K Parekh; Wenzhe Ho
Journal:  Virus Res       Date:  2012-06-21       Impact factor: 3.303

2.  Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes.

Authors:  J-P Liu; L Ye; X Wang; J-L Li; W-Z Ho
Journal:  Transpl Infect Dis       Date:  2010-10-07       Impact factor: 2.228

3.  Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative.

Authors:  Wataru Ito; Masaaki Toyama; Mika Okamoto; Masanori Ikeda; Koichi Watashi; Takaji Wakita; Yuichi Hashimoto; Masanori Baba
Journal:  Antivir Chem Chemother       Date:  2016-08-19

Review 4.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 5.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

6.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

Authors:  Helen Waller; Udayan Chatterji; Philippe Gallay; Tanya Parkinson; Paul Targett-Adams
Journal:  J Virol Methods       Date:  2010-02-02       Impact factor: 2.014

8.  HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Authors:  Udayan Chatterji; Precious Lim; Michael D Bobardt; Stefan Wieland; Daniel G Cordek; Gregoire Vuagniaux; Francis Chisari; Craig E Cameron; Paul Targett-Adams; Tanya Parkinson; Philippe A Gallay
Journal:  J Hepatol       Date:  2010-04-03       Impact factor: 25.083

9.  The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Authors:  Udayan Chatterji; Michael Bobardt; Suganya Selvarajah; Feng Yang; Hengli Tang; Noayo Sakamoto; Gregoire Vuagniaux; Tanya Parkinson; Philippe Gallay
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

10.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.